Apellis’ APL-2 Receives Orphan Drug Designation from the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
9
Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic anemia (AIHA).

AIHA refers to both cold agglutinin disease (CAD) and warm autoimmune hemolytic anemia (wAIHA.) Both rare autoimmune disorders are caused by pathogenic Immunoglobulin G (IgG) antibodies that react with RBC and can activate the complement system leading to the premature destruction of red blood cells. Both diseases are characterized by potentially life-threatening anemia and other acute complications. There are an estimated 10,000 CAD patients and 30,000 plus wAIHA patients across the United States and Europe. C3+ wAIHA has been estimated to represent as much as two thirds of the total wAIHA population. There are currently no approved treatments for CAD or wAIHA.

By targeting C3, the protein at the center of the entire complement system, Apellis believes APL-2 has the potential to eliminate the excessive and inappropriate C3 activation that is central to AIHA, thereby protecting the cells against complement-mediated intra- and extravascular destruction more completely than other approaches with more limited effects on the complement system.  Apellis is currently conducting a  Phase 2  trial of APL-2 in and open-label trial assessing the safety, tolerability, efficacy, and PK of multiple subcutaneous (SC) doses of APL-2 administered daily in patients with warm autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD).

“This orphan drug designation represents an important recognition by the FDA of APL-2’s potential to treat AIHA, a rare disease that can lead to potentially life-threatening anemia and hemolysis, as well as other acute complications, and for which there are no approved treatments currently for patients,” said Federico Grossi, EVP of clinical development and medical affairs. “This is an important milestone as we build out our pipeline using the systemic administration of APL-2 in rare, complement-mediated diseases, and we look forward to seeing the outcomes of our Phase 2 study.”

The FDA Orphan Drug program provides orphan designation to novel drugs that are intended for the treatment of rare diseases (those affecting fewer than 200,000 people in the United States). The designation provides sponsors with development and commercial incentives including seven years of market exclusivity in the US, consultation by FDA on clinical study design, potential for expedited drug development, and certain fee exemptions and reductions.

About APL-2  APL-2 is designed to inhibit the complement cascade centrally at C3 and may have the potential to treat a wide range of complement-mediated diseases more effectively than is possible with partial inhibitors of complement. APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b, effectively blocking all three pathways of complement activation (classical, lectin, and alternative). To date, APL-2 has generally been well-tolerated. No significant infections have been observed in trials involving the systemic administration of APL-2, including the trials in PNH, AIHA or other trials. 

About Apellis Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit  http://www.apellis.com . For additional information regarding our clinical trials, visit  www.apellis.com/clinical-trials.html .

Forward-Looking Statements  Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submissions and whether APL-2 will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies for AIHA or any other indication; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2018 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact: Tully Nicholas tnicholas@denterlein.com   617.482.0042  (office) 860.490.0218  (mobile)

Investor Contact: Alex Kane akane@w2ogroup.com 212.301.7218  (office) 929.400.2691  (mobile)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 61

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 146

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 18

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 246

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 196

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 9

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 35

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 34

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 116

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Abacus Global Management Inc. Stock

Updated Category News Views 231

Wolf Popper LLP Initiates Investigation for Investors In response to potential investor claims, Wolf Popper LLP has begun an investigation concerning the common stock of Abacus Global Management, Inc. (ABL). This action comes in light of significant recent developments that have raised concerns among shareholders. Background on Abacus Global Management Abacus Global...

Continue Reading
LM Funding America Inc. Reports Q3 2024 Results and Outlook

Updated Category News Views 115

Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...

Continue Reading
Siete Foods' Juntos Fund Celebrates 15 Latino-Owned Businesses

Updated Category News Views 239

Siete Foods launched its Juntos Fund back in 2024, dishing out a hefty $300,000 to uplift Latino small business owners. This initiative aimed at breaking down barriers for Latino entrepreneurs who often struggle to secure the financial backing they need. The winners? A mix of vibrant eateries and innovative food ventures that embody the rich essence of Latino culture...

Continue Reading
Discover the Fascinating Marilyn Monroe in New Documentary

Updated Category News Views 319

Big Screen Entertainment Group Unveils Marilyn Monroe Documentary Big Screen Entertainment Group (OTC: BSEG) has generated excitement with the release of its first trailer for an upcoming documentary focusing on the legendary actress Marilyn Monroe. This film, titled "Hollywood Legends: The Marilyn Monroe Story," promises to be a captivating tribute that delves into not...

Continue Reading
Transforming Dealerships: FrogData's New Marketing Solution

Updated Category News Views 120

FrogData Introduces FixedOps Velocity for Dealerships FrogData, a leader in advanced data analytics for the automotive industry, has recently launched a groundbreaking marketing solution called FixedOps Velocity. This innovative platform is aimed at helping dealership service departments enhance their marketing strategies significantly. The announcement comes just ahead...

Continue Reading